News | Embolic Protection Devices | April 20, 2018

Emboline Inc. Completes Funding for TAVR Embolic Protection Trial

Money will fund clinical trial for Emboliner Embolic Protection Catheter

Emboline Inc. Completes Funding for TAVR Embolic Protection Trial

April 20, 2018 — Emerging medical device company Emboline Inc. announced it has completed a Series B funding round totaling over $10 million for its total embolic protection device for transcatheter aortic valve replacement (TAVR) procedures. The funding includes $3 million in new equity financing from multiple investors led by SV Tech Ventures and Shangbay Capital, and over $7 million in conversion of previously-issued convertible notes.

"We have been closely monitoring the development of the Emboliner since 2015 and are encouraged by the potential this unique technology has to improve the safety of TAVR and other interventional procedures," said Peng Cheng, managing partner at SV Tech Ventures. "This is an exciting time for Emboline as they begin their clinical studies, and we look forward to continuing our work with the Emboline team to bring this technology to patients across the globe."

As part of the financing, ShangBay Capital's William Dai will join Cheng on the Emboline board of directors.

The working capital will be used to fund the SafePass Clinical trial for the Emboliner Embolic Protection Catheter, the subsequent European CE Mark submission and initial commercial launch.

"The risks of stroke and other neurological damage from TAVR have been getting increased attention in the cardiology community. We recognize that managing these risks will be critical to expanding TAVR into lower-risk patient populations," said William Dai, founding partner at ShangBay Capital.

The Emboliner is a next-generation approach to reducing the risk of cerebral embolic events or stroke that patients may face following TAVR procedures. The device’s design presents significant improvements on first-generation solutions by offering the following:

  • More effective coverage of all cerebral branches with fewer anatomical limitations;
  • Full-body embolic protection, capturing both cerebral and non-cerebral debris;
  • No additional procedural access required;
  • Minimal interference with devices necessary to complete the procedure; and
  • Outstanding ease-of-use and device control

For more information: www.emboline.com

 

Related Content

Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
Overlay Init